RT @ClinRheumatol: Editor Highlight – https://t.co/cNIqPSP4mA Long-term safety and effectiveness of tocilizumab in patients with rheumatoid…
RT @ClinRheumatol: Editor Highlight – https://t.co/cNIqPSP4mA Long-term safety and effectiveness of tocilizumab in patients with rheumatoid…
RT @ClinRheumatol: Editor Highlight – https://t.co/cNIqPSP4mA Long-term safety and effectiveness of tocilizumab in patients with rheumatoid…
RT @ClinRheumatol: Editor Highlight – https://t.co/cNIqPSP4mA Long-term safety and effectiveness of tocilizumab in patients with rheumatoid…
RT @ClinRheumatol: Editor Highlight – https://t.co/cNIqPSP4mA Long-term safety and effectiveness of tocilizumab in patients with rheumatoid…
Editor Highlight – https://t.co/cNIqPSP4mA Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice #OpenAccess https:
RT @ClinRheumatol: #OpenAccess in Clinical Rheumatology Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthr…
RT @ClinRheumatol: #OpenAccess in Clinical Rheumatology Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthr…
#OpenAccess in Clinical Rheumatology Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice https://t.co/tRrBAAHBlg